Matthews A, et al. - In women with a history of non-metastatic breast cancer, researchers examined the impact of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes. The totality of the randomized controlled trial and observational evidence suggested an increased risk of venous thromboembolism in tamoxifen users vs both non-users and aromatase inhibitor users. Data also indicated a higher risk of vascular diseases, myocardial infarction, and angina in aromatase inhibitor users vs tamoxifen users, which might be driven by a protective effect of tamoxifen.